scholarly journals Neuron-restrictive silencer factor–mediated downregulation of μ-opioid receptor contributes to the reduced morphine analgesia in bone cancer pain

Pain ◽  
2017 ◽  
Vol 158 (5) ◽  
pp. 879-890 ◽  
Author(s):  
Chao Zhu ◽  
Jun Tang ◽  
Tan Ding ◽  
Lei Chen ◽  
Wei Wang ◽  
...  
Keyword(s):  
Cancer Pain ◽  
Opioid Receptor ◽  
Bone Cancer ◽  
Bone Cancer Pain ◽  
Morphine Analgesia ◽  
Μ Opioid Receptor

scholarly journals Effect of the Norepinephrine Transporter (NET) Inhibition on μ-Opioid Receptor (MOR)-Induced Anti-nociception in a Bone Cancer Pain Model

2014 ◽  
Vol 125 (3) ◽  
pp. 264-273 ◽  
Author(s):  
Hiroko Ono ◽  
Atsushi Nakamura ◽  
Tomoe Kanbara ◽  
Kazuhisa Minami ◽  
Shunji Shinohara ◽  
...  
Keyword(s):  
Cancer Pain ◽  
Opioid Receptor ◽  
Bone Cancer ◽  
Norepinephrine Transporter ◽  
Bone Cancer Pain ◽  
Pain Model ◽  
Μ Opioid Receptor

scholarly journals Differential activation of the μ-opioid receptor by oxycodone and morphine in pain-related brain regions in a bone cancer pain model

2012 ◽  
Vol 168 (2) ◽  
pp. 375-388 ◽  
Author(s):  
Atsushi Nakamura ◽  
Minoru Hasegawa ◽  
Kazuhisa Minami ◽  
Tomoe Kanbara ◽  
Takako Tomii ◽  
...  
Keyword(s):  
Cancer Pain ◽  
Opioid Receptor ◽  
Bone Cancer ◽  
Brain Regions ◽  
Bone Cancer Pain ◽  
Pain Model ◽  
Differential Activation ◽  
Μ Opioid Receptor

scholarly journals Effects of Intraperitoneal and Intrathecal Morphine Analgesia on the Expression of μ-Opioid Receptors in Bone Cancer Pain Rats

Dose-Response ◽  
2019 ◽  
Vol 17 (4) ◽  
pp. 155932581988287 ◽  
Author(s):  
Wei Liu ◽  
Heqi Liu ◽  
Zongde Zhang ◽  
Jiapeng Huang
Keyword(s):  
Cancer Pain ◽  
Opioid Receptor ◽  
Intrathecal Morphine ◽  
Bone Cancer ◽  
Receptor Expression ◽  
Bone Cancer Pain ◽  
Control Group ◽  
Expression Levels ◽  
Significant Difference ◽  
Μ Opioid Receptor

Backgrounds: This study compared analgesic effects and μ-opioid receptor expression levels during long-term intraperitoneal and intrathecal treatment in a bone cancer pain rat. Methods: Twenty-four female Sprague-Dawley rats were injected Walker 256 tumor cells into the femur to create a bone cancer pain model. The control group was injected with saline intraperitoneally and intrathecally. The intraperitoneal group was injected with morphine intraperitoneally and saline intrathecally. The intrathecal group was injected saline intraperitoneally and morphine intrathecally. Changes in pain threshold, μ-opioid receptor expression levels in spinal cord, and tumor tissue were compared between 3 groups. Results: The intrathecal morphine group and the intraperitoneal group showed no difference in analgesia effects ( P > .05). Western blot and immunohistochemical staining of μ-opioid receptors demonstrated that its level in the intrathecal group was significantly lower than the intraperitoneal group ( P < .05) and without significant difference with the control group ( P > .05). The expression levels of μ-opioid receptor in the spinal cord tissue did not reveal a difference among these 3 groups ( P > .05). Conclusion: Intrathecal group and intraperitoneal group showed significant difference in μ-opioid receptor expressions although with no difference in analgesia effects. Long-term intrathecal morphine administration provided similar analgesia compared to systemic morphine.

The Roles of Chemokine CXCL13 in the Development of Bone Cancer Pain and the Regulation of Morphine Analgesia in Rats

Neuroscience ◽  
2019 ◽  
Vol 406 ◽  
pp. 62-72 ◽  
Author(s):  
Hui-Lian Bu ◽  
Yu-Zhong Xia ◽  
Pan-Mei Liu ◽  
Hai-Ming Guo ◽  
Chang Yuan ◽  
...  
Keyword(s):  
Cancer Pain ◽  
Bone Cancer ◽  
Bone Cancer Pain ◽  
Morphine Analgesia

scholarly journals Blocking mammalian target of rapamycin alleviates bone cancer pain and morphine toleranceviaµ-opioid receptor

2015 ◽  
Vol 138 (8) ◽  
pp. 2013-2020 ◽  
Author(s):  
Zongming Jiang ◽  
Shaoyong Wu ◽  
Xiujuan Wu ◽  
Junfeng Zhong ◽  
Anqing Lv ◽  
...  
Keyword(s):  
Cancer Pain ◽  
Opioid Receptor ◽  
Mammalian Target Of Rapamycin ◽  
Bone Cancer ◽  
Target Of Rapamycin ◽  
Bone Cancer Pain

scholarly journals Morphine analgesia and μ opioid receptor signaling require programed death protein 1

2019 ◽  
Author(s):  
Zilong Wang ◽  
Changyu Jiang ◽  
Qianru He ◽  
Megumi Matsuda ◽  
Qingjian Han ◽  
...  
Keyword(s):  
Opioid Receptor ◽  
Intrathecal Injection ◽  
Bone Cancer ◽  
Calcium Currents ◽  
Receptor Signaling ◽  
Morphine Analgesia ◽  
Drg Neurons ◽  
Spinal Cord Neurons ◽  
Μ Opioid Receptor ◽  
Cell Death Protein

SummaryOpioids such as morphine produce analgesia via mu opioid receptor (MOR), but opioid receptor signaling is not fully understood. Here we report that morphine analgesia and MOR signaling require neuronal Programmed cell death protein-1 (PD-1). We found that morphine-induced antinociception following systemic or intrathecal injection was compromised in Pd1-/- mice. Morphine analgesia was also abrogated in wild-type mice after treatment with Nivolumab, a clinically used anti-PD-1 monoclonal antibody. Morphine produced analgesia by suppressing calcium currents in DRG neurons and excitatory synaptic transmission in spinal cord neurons, but strikingly, both actions were impaired by PD-1 blockade. In a mouse model of bone cancer, the antinociceptive action of systemic morphine was compromised in Pd1-/- mice. Finally, PD-L1 and morphine produce synergistic analgesia. Our findings demonstrate that PD-1 also acts as a neuro checkpoint inhibitor and mediates opioid-induced analgesia and MOR signaling in neurons.

Sign in / Sign up

Export Citation Format

Share Document